IE38614L - Corticosteroid preparations - Google Patents
Corticosteroid preparationsInfo
- Publication number
- IE38614L IE38614L IE732216A IE221673A IE38614L IE 38614 L IE38614 L IE 38614L IE 732216 A IE732216 A IE 732216A IE 221673 A IE221673 A IE 221673A IE 38614 L IE38614 L IE 38614L
- Authority
- IE
- Ireland
- Prior art keywords
- layer
- corticosteroid
- prednisolone
- soluble
- taken
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 7
- 238000002360 preparation method Methods 0.000 title 1
- 229960005205 prednisolone Drugs 0.000 abstract 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 210000004051 gastric juice Anatomy 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 abstract 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000021152 breakfast Nutrition 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 229960004544 cortisone Drugs 0.000 abstract 1
- 229960003290 cortisone acetate Drugs 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 229960004584 methylprednisolone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000001360 synchronised effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1458676 Corticosteroid compositions HOECHST AG 10 Dec 1973 [9 Dec 1972] 57090/73 Heading A5B A controlled release unit dosage pharmaceutical composition for oral administration comprises at least two layers, the word "layer" including a core in its meaning (e.g. drageÚ cores), each comprising a corticosteroid in the form of the free alcohol or an ester or salt thereof and each having different release properties. The corticosteroid may be hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, or esters or salts thereof. Each layer may contain the same or different corti- 'costeroids, e.g. prednisolone in one layer and its acetate in another, or cortisone acetate in one layer and prednisolone in another. The preferred form is a dregÚe core such as a pressed tablet as the one corticosteroid-containing layer, having an enteric coat (e.g. cellulose acetate phthalate) resistant to gastric juice but soluble in the dudodenum, and an outer dragÚe coating containing corticosteroid, this coating being freely soluble in gastric juice to liberate its active ingredient for absorption in the stomach. The compositions are intended to enable the corticosteroid to be administered in such a way that its absorption rate and action is synchronised with the circadian rhythm of physiological ACTH secretion, and accordingly, the preferred form provides a small steroid dose immediately (i.e. from the outer, soluble layer), and a larger dose some hours later (i.e. from the inner, enterically coated layer), the dosage form being intended to be taken early in the morning. The invention includes a pack comprising a card carrying at least one pair of inventive unit dosage forms together with instruction that one unit is to be taken at about breakfast time and the other unit is to be taken between midafternoon and bed-time.
[GB1458676A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2260384A DE2260384C3 (en) | 1972-12-09 | 1972-12-09 | Oral corticosteroid preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE38614L true IE38614L (en) | 1974-06-09 |
| IE38614B1 IE38614B1 (en) | 1978-04-26 |
Family
ID=5864005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2216/73A IE38614B1 (en) | 1972-12-09 | 1973-12-07 | Orally administrable corticosteroid preparations |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS4986527A (en) |
| KR (1) | KR780000243B1 (en) |
| AT (1) | AT345983B (en) |
| BE (1) | BE808442A (en) |
| CA (1) | CA1027864A (en) |
| DE (1) | DE2260384C3 (en) |
| FR (1) | FR2209585B1 (en) |
| GB (1) | GB1458676A (en) |
| HU (1) | HU171907B (en) |
| IE (1) | IE38614B1 (en) |
| IL (1) | IL43764A (en) |
| NL (1) | NL7316585A (en) |
| ZA (1) | ZA739327B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1392321B1 (en) * | 2001-03-15 | 2010-08-18 | Soligenix, Inc. | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| NZ551336A (en) | 2004-04-22 | 2010-04-30 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| SE0401031D0 (en) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| CN102448464A (en) * | 2009-04-07 | 2012-05-09 | 杜奥科特药物公司 | Improved glucocorticoid therapy |
| EP3403654B1 (en) * | 2009-10-01 | 2019-07-31 | Adare Development I, L.P. | Orally administered corticosteroid compositions |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| TWI777515B (en) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | Methods of treating eosinophilic esophagitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB862376A (en) * | 1957-10-10 | 1961-03-08 | Pfizer & Co C | Sustained release pharmaceutical tablet |
-
1972
- 1972-12-09 DE DE2260384A patent/DE2260384C3/en not_active Expired
-
1973
- 1973-12-03 KR KR7302039A patent/KR780000243B1/en not_active Expired
- 1973-12-03 FR FR7343036A patent/FR2209585B1/fr not_active Expired
- 1973-12-04 NL NL7316585A patent/NL7316585A/xx not_active Application Discontinuation
- 1973-12-06 IL IL43764A patent/IL43764A/en unknown
- 1973-12-06 CA CA187,580A patent/CA1027864A/en not_active Expired
- 1973-12-06 HU HU73HO00001633A patent/HU171907B/en unknown
- 1973-12-07 AT AT1026773A patent/AT345983B/en active
- 1973-12-07 ZA ZA739327A patent/ZA739327B/en unknown
- 1973-12-07 IE IE2216/73A patent/IE38614B1/en unknown
- 1973-12-08 JP JP48137285A patent/JPS4986527A/ja active Pending
- 1973-12-10 BE BE138701A patent/BE808442A/en unknown
- 1973-12-10 GB GB5709073A patent/GB1458676A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2209585B1 (en) | 1977-09-02 |
| AU6328073A (en) | 1975-06-12 |
| IL43764A0 (en) | 1974-03-14 |
| ZA739327B (en) | 1974-10-30 |
| CA1027864A (en) | 1978-03-14 |
| HU171907B (en) | 1978-04-28 |
| GB1458676A (en) | 1976-12-15 |
| JPS4986527A (en) | 1974-08-19 |
| ATA1026773A (en) | 1978-02-15 |
| DE2260384C3 (en) | 1979-11-29 |
| FR2209585A1 (en) | 1974-07-05 |
| DE2260384A1 (en) | 1974-06-12 |
| IE38614B1 (en) | 1978-04-26 |
| DE2260384B2 (en) | 1979-04-12 |
| BE808442A (en) | 1974-06-10 |
| AT345983B (en) | 1978-10-10 |
| NL7316585A (en) | 1974-06-11 |
| IL43764A (en) | 1977-03-31 |
| KR780000243B1 (en) | 1978-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6423340B1 (en) | Method for the treatment of inflammatory bowel diseases | |
| US3131123A (en) | Enteric tablets and manufacture thereof | |
| US3431338A (en) | Coated dosage form adapted to oral emetine or dehydroemetine therapy | |
| US5316772A (en) | Bilayered oral pharmaceutical composition with pH dependent release | |
| JPH0258246B2 (en) | ||
| US20020102308A1 (en) | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals | |
| US4261971A (en) | Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer | |
| SI8710681A8 (en) | Process for obtaining new pharmaceutic substance for oral use | |
| JPS5959633A (en) | Manufacture of release controlled composite unit composition | |
| GB1507521A (en) | Dosage unit | |
| NO174952B (en) | Process for the preparation of an oral pharmaceutical composition which is stable against discoloration and which contains an acid-labile compound | |
| JPS63287720A (en) | Pharmaceutical lumber | |
| JP2792904B2 (en) | Pharmaceutical preparation for oral administration that releases controlled release of active substance and method for producing the same | |
| EP0164967A2 (en) | Pharmaceutical composition of sparingly soluble medicament and method for its preparation | |
| JPS6348219A (en) | Pharmaceutical composition containing dipyridamol or mopidamol and o-acetylsalicylic acid or physiologically tolerated salts of them, manufacture and use for clot formation | |
| US2099402A (en) | Pill or tablet | |
| GB1161439A (en) | Pharmaceutical Compositions | |
| JPS63233998A (en) | Pharmaceutical composition containing fluticasone propionate | |
| JPS61275211A (en) | Therapeutical drug particle | |
| EP0425699B1 (en) | Oral preparation which can be released at suitable region in intestine | |
| IE38614L (en) | Corticosteroid preparations | |
| JPH02164821A (en) | Novel dosing method | |
| Neustadt | Corticosteroid therapy in rheumatoid arthritis: comparative study of effects of prednisone and prednisolone, methylprednisolone, triamcinolone, and dexamethasone | |
| EP0472645A1 (en) | Osmotic dosage form. | |
| DE10012555A1 (en) | Composition for rapid release of corticoid drugs after delay period, useful for drug delivery during the night, e.g. for preventing asthma, or for delivery to colon for treating inflammatory bowel disease |